Share

July 2021; 8 (4) ArticleOpen Access

Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes

Francesc Graus, Alberto Vogrig, Sergio Muñiz-Castrillo, Jean-Christophe G. Antoine, Virginie Desestret, Divyanshu Dubey, Bruno Giometto, Sarosh R. Irani, Bastien Joubert, Frank Leypoldt, Andrew McKeon, Harald Prüss, Dimitri Psimaras, Laure Thomas, Maarten J. Titulaer, Christian A. Vedeler, Jan J. Verschuuren, Josep Dalmau, Jerome Honnorat
First published May 18, 2021, DOI: https://doi.org/10.1212/NXI.0000000000001014
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
7276

Share

Article Information

vol. 8 no. 4 e1014
DOI: 
https://doi.org/10.1212/NXI.0000000000001014
PubMed: 
34006622
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • Received November 18, 2020
  • Accepted in final form February 22, 2021
  • First Published May 18, 2021.
Copyright & Usage: 
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Author Disclosures

    1. Francesc Graus, MD, PhD* (francesc.graus{at}idibaps.org),
    2. Alberto Vogrig, MD* (alberto.vogrig{at}gmail.com),
    3. Sergio Muñiz-Castrillo, MD* (ext-sergio.muniz{at}chu-lyon.fr),
    4. Jean-Christophe G. Antoine, MD, PhD (j.christophe.antoine{at}chu-st-etienne.fr),
    5. Virginie Desestret, MD, PhD (virginie.desestret{at}chu-lyon.fr),
    6. Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu),
    7. Bruno Giometto, MD (bruno.giometto{at}apss.tn.it),
    8. Sarosh R. Irani, MD, PhD (sarosh.irani{at}ndcn.ox.ac.uk),
    9. Bastien Joubert, MD, PhD (bastien.joubert{at}chu-lyon.fr),
    10. Frank Leypoldt, MD, PhD (frank.leypoldt{at}uksh.de),
    11. Andrew McKeon, MD (mckeon.andrew{at}mayo.edu),
    12. Harald Prüss, MD (harald.pruess{at}charite.de),
    13. Dimitri Psimaras, MD (dimitri.psimaras{at}aphp.fr),
    14. Laure Thomas, MD (laure.thomas{at}chu-lyon.fr),
    15. Maarten J. Titulaer, MD, PhD (m.titulaer{at}erasmusmc.nl),
    16. Christian A. Vedeler, MD, PhD (christian.alexander.vedeler{at}helse-bergen.no),
    17. Jan J. Verschuuren, MD, PhD (j.j.g.m.verschuuren{at}lumc.nl),
    18. Josep Dalmau, MD, PhD (josep.dalmau{at}uphs.upenn.edu) and
    19. Jerome Honnorat, MD, PhD
  1. Francesc Graus, MD, PhD* (francesc.graus{at}idibaps.org),
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Associated Editor for MedLink Neurology

    Patents:

    1. I hold a patent for the use of IgLON5 antibodies as diagnostic test

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. I receive royalties from Euroimmun for the use of IgLON5 as an autoantibody test

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Alberto Vogrig, MD* (alberto.vogrig{at}gmail.com),
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. BMC Neurology, Editorial Board Member, 2020-2021

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. European Academy of Neurology (EAN)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Sergio Muñiz-Castrillo, MD* (ext-sergio.muniz{at}chu-lyon.fr),
  4. Jean-Christophe G. Antoine, MD, PhD (j.christophe.antoine{at}chu-st-etienne.fr),
    5. Scientific Advisory Boards:

    1. Association Française contre les Myopathies

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. Pfizer-Travel

    Editorial Boards:

    1. NONE

    Patents:

    1. Patents on the use of anti-CRMP5 and anti-FGFR3 antibodies for diagnostic purpose

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Pfizer

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Virginie Desestret, MD, PhD (virginie.desestret{at}chu-lyon.fr),
    6. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  6. Divyanshu Dubey, MD (dubey.divyanshu{at}mayo.edu),
  7. Bruno Giometto, MD (bruno.giometto{at}apss.tn.it),
    8. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  8. Sarosh R. Irani, MD, PhD (sarosh.irani{at}ndcn.ox.ac.uk),
    9. Scientific Advisory Boards:

    1. Encephalitis Society and Autoimmune Encephalitis Alliance (non-profit, charity). ADC therapeutics, Immunovant and UCB (commercial)

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. SRI has received honoraria for speaking at scientific conferences, including the Movement Disorder Society, Dublin Neuroimunology Symposium, Korean Encephalitis meeting and Bethel Epilepsy Symposium.

    Editorial Boards:

    1. NONE

    Patents:

    1. SRI receives royalties on patent application WO/2010/046716 entitled 'Neurological Autoimmune Disorders'. The patent has been licensed for the development of assays for LGI1 and other VGKC-complex antibodies.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. 1. Commercial. MedImmune Ltd. 2. ADCT 3. Minnetronix Neuro Inc 4. UCB Pharma 5. Medicolegal projects (various)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Commercial: SRI has received research funding from UCB, CSL Behring and ONO pharmaceuticals

    Research Support, Government Entities:

    1. S.R.I has received a NIHR fellowship, Department of Health, UK to fund his DPhil/PhD

    Research Support, Academic Entities:

    1. SRI received funding support from a Wellcome Intermediate Clinical Fellowship, BMA Research Grants - Vera Down grant, the Fulbright UK- US commission and the MS society (2012-2013).

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. For VGKC-complex antibody patent, as described above. Royalties paid by OUI.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  9. Bastien Joubert, MD, PhD (bastien.joubert{at}chu-lyon.fr),
    10. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. European Academy of Neurology awarded the following grant: EAN Research Training Fellowship 2019 Institut Servier Research Grant 2020

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  10. Frank Leypoldt, MD, PhD (frank.leypoldt{at}uksh.de),
    11. Scientific Advisory Boards:

    1. (1) Roche (2) Biogen (3) Alexion (4) Novartis

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. (1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer (6) Novartis (6) Roche (6) Novartis (7) Merck (8) Roche (9) Alexion

    Editorial Boards:

    1. Neurology: Neuroimmunology and Neuroinflammation

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical procedures or imaging studies:

    1. Institute of Laboratory Medicine, University Hospital Schleswig- Holstein Campus Kiel, Germany, commercial antibody testing service, 20%

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. (1) German Ministry of Education and Research (BMBF) Speaker, PI 2019 01GM1908A (2) German Research Council (GRC, DFG), PI, 2019 LE 3064/2-1

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  11. Andrew McKeon, MD (mckeon.andrew{at}mayo.edu),
    12. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. I am a member of the editorial board of Neurology: Neuroimmunology and Neuroinflammation

    Patents:

    1. Patent applications pending: Septin 5, Septin 7, GFAP, PDE10A, Kelch-11 and MAP1B as markers of neurological autoimmunity and paraneoplastic disorders

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Euroimmun Alexion

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  12. Harald Prüss, MD (harald.pruess{at}charite.de),
  13. Dimitri Psimaras, MD (dimitri.psimaras{at}aphp.fr),
    14. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  14. Laure Thomas, MD (laure.thomas{at}chu-lyon.fr),
    15. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  15. Maarten J. Titulaer, MD, PhD (m.titulaer{at}erasmusmc.nl),
    16. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. (1) Neurology: Neuroimmunology & Neuroinflammation, since June 2014

    Patents:

    1. (1) filed a patent for "methods for typing neurological disorders and cancer, and devices for use therein" specifically about diagnostics for anti-GABAB receptor antibodies and KCTD antibodies.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. (1) Guidepoint Global LLC, research funds for consultancy; (2) Novartis, research funds for teaching; (3) unrestricted research grant from Euroimmun AG.

    Research Support, Government Entities:

    1. (1) supported by the Netherlands Organisation for Scientific Research (NWO, Veni incentive and Memorabel initiative)

    Research Support, Academic Entities:

    1. (1) Previously supported by an ErasmusMC fellowship

    Research Support, Foundations and Societies:

    1. (1) supported by the Dutch Epilepsy Foundations, projectnumbers 14-19 and 19-08.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  16. Christian A. Vedeler, MD, PhD (christian.alexander.vedeler{at}helse-bergen.no),
    17. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  17. Jan J. Verschuuren, MD, PhD (j.j.g.m.verschuuren{at}lumc.nl),
    18. Scientific Advisory Boards:

    1. Myasthenia Foundation of America (MGFA) medical/scientific advisory board. Study Steering Committee of Argenx. Advisory meeting for Rapharma.

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. World Muscle Society, travel grant for keynote speaker lecture

    Editorial Boards:

    1. Journal of Neuromuscular Diseases, member editorial board, 2014-now

    Patents:

    1. Patents on MuSK myasthenia gravis

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. The Neurology department of the LUMC has received fees from Argen-X, and NMDPharma because of consultancies

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Argenx and NMDPharma research agreement

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Princes Beatrix Spierfonds, grant for MG research, Prinicpal investigator.

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. The LUMC received royalties for a diagnostic antibody test from TECAN/IBL.

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  18. Josep Dalmau, MD, PhD (josep.dalmau{at}uphs.upenn.edu) and
    19. Scientific Advisory Boards:

    1. SAGE therapeutics

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Neuroimmunology and Neuroinflammation Neurology Annals Neurology

    Patents:

    1. Patent for Ma2 autoantibody test: US 6,387,639; Issued May 14th, 2002. Patent for NMDA receptor autoantibody test: US 7,972,796 B2 July 5, 2011; European 2057466. Patent for GABAb receptor autoantibody test: US 8,685,656; European 2483417; Patents filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test.

    Publishing Royalties:

    1. Neurology- UpToDate, Wolters Kluwer contributing author, receive royalties Medlink Neurology contributing author, receive royalties

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Advance Medical

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support (allosteric modulation of NMDAR) from SAGE Therapeutics

    Research Support, Government Entities:

    1. -Instituto Carlos III/FEDER (FIS, 17/00234, CIBERER CB15/00010, Proyectos Integrados de Excelencia, PIE 16/00014 and AC18/00009). -Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR), and CERCA Programme Generalitat de Catalunya

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. Safra Foundation Sage therapeutics Cellex Foundation La Caixa Health Foundation

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. Ma2 autoantibody test (tech/invention), Athena Diagostics via Memoral Sloan Kettering, current NMDA receptor, GABA(B) receptor autoantibody tests (tech/invention), Euroimmun, Inc via University of Pennsylvania, current GABA(A) receptor, DPPX and IgLON5 autoantibody tests (tech/invention), Euroimmun, Inc via Institucio Catalana de Recerca i Estudis Avancats (ICREA); Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), current

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  19. Jerome Honnorat, MD, PhD
    20. Scientific Advisory Boards:

    1. Scientific advisory board for Bristol Meyers Squibb

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. receives royalties from licensing fees to Athena Diagnostics, Euroimmun, and ravo Diagnostika for a patent for the use of CV2/CRMP5 as diagnostic tests.

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Research support from CSL Behring France

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Neuroimmunology Program (F.G., J.D.), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centre de Référence National pour les Syndromes Neurologiques Paranéoplasique (A.V., S.M.-C., J.-C.G.A., V.D., B.J., L.T., J.H.), Hôpital Neurologique, Hospices Civils de Lyon; SynatAc Team (A.V., S.M.-C., V.D., B.J., L.T., J.H.), NeuroMyoGene Institute, INSERM U1217/CNRS UMR5310, Lyon; Université Claude Bernard Lyon 1 (A.V., S.M.-C., V.D., B.J., L.T., J.H.), Université de Lyon; Service de Neurologie (J.-C.G.A.), CHU de Saint-Etienne, France; Department of Neurology (D.D., A.M.), Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; Neurology Unit (B.G.), Trento Hospital, Azienda Provinciale per I Servizi Sanitari (APSS) di Trento, Italy; Oxford Autoimmune Neurology Group (S.R.I.), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, United Kingdom; Neuroimmunology Section (F.L.), Institute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel/Lübeck; German Center for Neurodegenerative Diseases (DZNE) Berlin (H.P.), and Department of Neurology and Experimental Neurology (H.P.), Charité–Universitätsmedizin Berlin, Germany; Centre de Compétence des Syndromes Neurologiques Paranéoplasiques et Encéphalites Autoimmunes (D.P.), Groupe Hospitalier Pitié-Salpêtrière, Paris, France; Department of Neurology 2 Mazarin (D.P.), and INSERM U 1127 (D.P.), CNRS UMR 7225, Centre de Recherche de l'Institut du Cerveau et de la Moelle Epinière Groupe, Hospitalier Pitié-Salpêtriêre et Université Pierre et Marie Curie-Paris 6, AP-HP, France; Department of Neurology (M.J.T.), Erasmus MC University Medical Center, Rotterdam, the Netherlands; Department of Clinical Medicine (C.A.V.), University of Bergen; Department of Neurology (C.A.V.), Haukeland University Hospital; Neuro-SysMed–Centre of Excellence for Experimental Therapy in Neurology (C.A.V.), Departments of Neurology and Clinical Medicine, Bergen, Norway; and Neurology Department (J.J.V.), Leiden University Medical Center, the Netherlands.
  1. Correspondence
    Dr. Honnorat jerome.honnorat{at}chu-lyon.fr
View Full Text

Article usage

Article usage: May 2021 to June 2022

AbstractFullPdfSource
May 20211832931030Highwire
Jun 20212581217698Highwire
Jul 20211691522830Highwire
Aug 2021281197590Highwire
Sep 202129815368Highwire
Oct 202128870394Highwire
Nov 202124784411Highwire
Dec 202114652297Highwire
Jan 202218824363Highwire
Feb 202215860338Highwire
Mar 2022351158426Highwire
Apr 2022251105644Highwire
May 2022351078455Highwire
Jun 2022171006432Highwire

Cited By...

Letters: Rapid online correspondence

Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

Topics Discussed

Alert Me

Advertisement